Venshiv Pharma Chem Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 17-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.10 Cr
as on 17-12-2024
- Revenue %
(FY 2020)
- Profit 17.79%
(FY 2020)
- Ebitda -1894.18%
(FY 2020)
- Net Worth -0.96%
(FY 2020)
- Total Assets 7.08%
(FY 2020)
About Venshiv Pharma Chem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹6.10 Cr.
Kudumula Reddy and Kudumla Reddy serve as directors at the Company.
- CIN/LLPIN
U24232TG2007PTC053592
- Company No.
053592
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Apr 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Venshiv Pharma Chem Private Limited offer?
Venshiv Pharma Chem Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Pharma Ingredients & Raw Materials, API Intermediate, Chemical Reagents & Catalysts, Catalysts, Chemical Compound, Nickel Catalysts.
Who are the key members and board of directors at Venshiv Pharma Chem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kudumula Reddy  | Additional Director | 20-May-2013 | Current |
| Kudumla Reddy | Director | 14-Apr-2007 | Current |
Financial Performance of Venshiv Pharma Chem.
Venshiv Pharma Chem Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 17.79% increase in profit. The company's net worth dipped by a decrease of 0.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venshiv Pharma Chem?
In 2023, Venshiv Pharma Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 31 May 2011 | ₹6.10 Cr | Open |
How Many Employees Work at Venshiv Pharma Chem?
Unlock and access historical data on people associated with Venshiv Pharma Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venshiv Pharma Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venshiv Pharma Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
